Primary CNS Lymphoma (PCNSL)

Primary CNS lymphoma (PCNSL) is a rare, aggressive extranodal non-Hodgkin lymphoma that is confined to the central nervous system — including the brain parenchyma, spinal cord, leptomeninges, cranial nerves, and eyes — without evidence of systemic lymphoma outside the CNS. Although it accounts for fewer than 5% of all primary brain tumors, PCNSL has attracted intense clinical and research interest because its presentation can mimic other neurologic conditions, its management involves highly specialized chemotherapy capable of crossing the blood-brain barrier, and its prognosis has improved substantially over the past two decades with modern high-dose methotrexate-based regimens.

Table of Contents

1. Overview and Epidemiology
2. Pathophysiology and Molecular Features
3. Immunosuppression and Risk Factors
4. Clinical Presentation
5. Neuroimaging
6. Vitreoretinal Lymphoma
7. Diagnosis and Workup
8. Critical: Steroids Before Biopsy
9. Treatment
10. Prognosis
11. Key Research Papers
12. PubMed Topic Searches
13. Connections
14. Featured Videos

1. Overview and Epidemiology

PCNSL represents approximately 3–4% of all newly diagnosed primary brain tumors and approximately 1% of all non-Hodgkin lymphomas. The incidence in the United States is approximately 5 cases per million people per year, with approximately 1,500–2,000 new cases diagnosed annually. Historically, PCNSL was strongly associated with HIV/AIDS, but the advent of combination antiretroviral therapy (cART) in the mid-1990s dramatically reduced the incidence in HIV-infected individuals. Today, the majority of PCNSL cases in Western countries occur in immunocompetent patients, typically in the sixth through eighth decades of life.

Key epidemiologic features:

• Age: Bimodal distribution — immunocompromised patients (particularly HIV/AIDS) present at younger ages (median ~30–40 years in the pre-cART era); immunocompetent PCNSL presents at median age 60–65 years.
• Sex: Slight male predominance in immunocompetent cases; more pronounced in HIV-associated PCNSL.
• Incidence trend: Declining in HIV-positive patients (due to cART); rising in immunocompetent elderly patients, likely due to aging population, more frequent use of immunosuppressive drugs (transplant, autoimmune diseases), and improved neuroimaging detection.
• Histology: Over 90% are diffuse large B-cell lymphoma (DLBCL). Rare subtypes include T-cell PCNSL (<5%), Burkitt lymphoma in immunocompromised patients, and marginal zone lymphoma (rare).

Back to Table of Contents

2. Pathophysiology and Molecular Features

PCNSL DLBCL has a distinct molecular profile that sets it apart from systemic DLBCL, consistent with an activated B-cell (ABC) subtype with unique adaptations to the CNS microenvironment:

• MYD88 L265P mutation: Present in 70–80% of PCNSL cases (compared to ~30% of systemic ABC-DLBCL). MYD88 L265P activates NF-κB signaling and JAK-STAT pathways, promoting B-cell survival. This mutation is now used as a diagnostic biomarker in CSF cell-free DNA testing and vitreoretinal lymphoma diagnosis.
• CD79B mutation: Co-occurs with MYD88 L265P in approximately 40% of PCNSL; further amplifies B-cell receptor (BCR) and NF-κB signaling. The combination of MYD88 L265P + CD79B mutation is highly specific for CNS-type DLBCL.
• Loss of HLA expression: PCNSL frequently downregulates HLA class I and II molecules, allowing immune evasion within the CNS microenvironment, which is already immune-privileged due to the blood-brain barrier.
• PD-L1 overexpression: Common in PCNSL; implicated in immune escape and currently under investigation as a therapeutic target with checkpoint inhibitors.
• Chromosomal gains: Frequent gains at 18q21 (BCL2, MALT1), 12q12, and deletions at 6q21 (PRDM1/Blimp-1).
• EBV: Epstein-Barr virus is the causative driver of virtually all HIV-associated PCNSL (detected in tumor cells by EBER in situ hybridization in nearly 100% of HIV-positive cases with CD4 <50 cells/μL), as well as post-transplant PCNSL. EBV is absent in immunocompetent PCNSL.

The blood-brain barrier creates a pharmacologically challenging microenvironment: most conventional chemotherapy agents cannot penetrate adequately. This explains why systemic DLBCL regimens such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) are largely ineffective in PCNSL despite their activity in systemic disease.

Back to Table of Contents

3. Immunosuppression and Risk Factors

Immunosuppression is the most important known risk factor for PCNSL, operating through well-defined mechanisms:

• HIV/AIDS: Before cART, PCNSL developed in approximately 2–6% of patients with AIDS, almost exclusively in those with profound CD4 lymphopenia (typically <50 cells/μL). In this setting, EBV is the direct causative agent — EBV-infected B-cells normally kept in check by CD8+ cytotoxic T-cells are released from immune surveillance, leading to unrestricted B-cell proliferation within the CNS. With cART, CD4 counts recover and PCNSL incidence has declined dramatically. FDG-PET and thallium SPECT are used to differentiate PCNSL from cerebral toxoplasmosis in AIDS patients when tissue biopsy carries prohibitive risk.
• Post-transplant immunosuppression: Solid organ transplant recipients and allogeneic hematopoietic stem cell transplant patients receiving calcineurin inhibitors (tacrolimus, cyclosporine) are at risk for post-transplant lymphoproliferative disorder (PTLD), which may manifest as CNS involvement. PTLD is largely EBV-driven; reducing immunosuppression is a key first step in management.
• Congenital immunodeficiencies: Wiskott-Aldrich syndrome, severe combined immunodeficiency (SCID), and other primary immunodeficiencies are associated with EBV-driven lymphoproliferative disorders including PCNSL.
• Iatrogenic immunosuppression: Long-term methotrexate (low-dose, for rheumatoid arthritis) and other immunosuppressive therapies for autoimmune diseases are associated with occasional EBV-positive lymphomas; in some cases, drug withdrawal leads to regression.
• Immunocompetent PCNSL: In the majority of current Western cases, no underlying immunosuppression is identified. The pathogenesis in this population is not fully understood but involves the molecular alterations (MYD88, CD79B) described above, possibly facilitated by age-related immune senescence.

Back to Table of Contents

4. Clinical Presentation

PCNSL can present with a variety of neurologic and ophthalmologic symptoms, reflecting its predilection for the cerebral hemispheres, deep gray structures, periventricular white matter, and eyes. The onset is typically subacute (days to weeks), distinguishing it from stroke (sudden) and primary brain tumors (slower).

Common presentations by compartment:

• Cerebral parenchyma (most common): Focal neurologic deficits (hemiparesis, aphasia, visual field defects, ataxia) corresponding to lesion location; cognitive changes (memory impairment, executive dysfunction, personality change) — particularly with frontal lobe or periventricular involvement; headache and signs of raised intracranial pressure (papilledema, nausea/vomiting) in approximately 30% of cases.
• Neuropsychiatric symptoms: Behavioral change, personality alteration, psychosis, or depression may be the presenting complaint, especially with frontal or corpus callosum involvement. PCNSL should be considered in the differential of new-onset neuropsychiatric symptoms in older adults.
• Seizures: Approximately 10–15% at presentation; less common than in glioma because PCNSL predominantly involves deeper structures rather than cortex.
• Leptomeningeal involvement: Cranial nerve palsies, radiculopathy, meningismus, or hydrocephalus.
• Spinal cord: Rare (<5% at diagnosis); paraparesis, sensory level, or sphincter dysfunction.
• Vitreoretinal: Covered separately below; blurred vision, "floaters," painless visual deterioration.

Back to Table of Contents

5. Neuroimaging

MRI with gadolinium contrast is the modality of choice. The classic imaging appearance of immunocompetent PCNSL is highly characteristic and differs importantly from glioblastoma:

• Enhancement pattern: Homogeneous, solid contrast enhancement — contrasting sharply with glioblastoma, which typically shows ring-enhancing enhancement around a central necrotic core. PCNSL rarely shows ring enhancement in immunocompetent patients (ring enhancement is more common in HIV-positive PCNSL).
• Location: Deep structures and periventricular regions — basal ganglia, thalamus, corpus callosum, periventricular white matter — in approximately 60% of cases. This "contact with the CSF space" is a characteristic feature that reflects the angiocentric growth pattern and lymphocyte trafficking behavior of B-cells.
• Restricted diffusion: Hyperintense on DWI (diffusion-weighted imaging) due to high nuclear-to-cytoplasmic ratio and dense cellular packing, reflecting restricted water diffusion. This feature helps differentiate PCNSL from high-grade glioma and metastasis.
• T2/FLAIR signal: Iso- to hypointense on T2 (unlike glioblastoma, which is typically T2-hyperintense), again reflecting hypercellularity.
• Multifocal lesions: Present in approximately 30–40% of immunocompetent PCNSL (60–80% of HIV-associated PCNSL). The "butterfly" pattern across the corpus callosum, also seen in glioblastoma, can be a presenting feature.
• After steroids: PCNSL can regress dramatically and become invisible on MRI within 48–72 hours of corticosteroid administration — the so-called "ghost tumor." This is pathognomonic of PCNSL but is diagnostically disastrous if steroids are given before biopsy (see steroid warning section).

FDG-PET/CT of the body and testicular ultrasound (in males) are performed to exclude systemic lymphoma and confirm CNS-only disease, which is required for the PCNSL diagnosis.

Back to Table of Contents

6. Vitreoretinal Lymphoma (VRL)

Vitreoretinal lymphoma (also called primary intraocular lymphoma, PIOL) is a subset of PCNSL in which lymphoma cells infiltrate the vitreous humor, retina, or optic nerve. VRL occurs in approximately 15–25% of PCNSL patients, either concurrently with brain disease or preceding neurologic symptoms by months to years. Conversely, approximately 65–90% of patients presenting with VRL will develop brain PCNSL over time, so VRL should be considered a direct harbinger of CNS disease.

Presentation: painless, progressive visual disturbance — blurred vision, "floaters" (vitreous cells), scotomata, photophobia. The appearance on slit-lamp examination shows characteristic large lymphoma cells in the vitreous (described as "clouds of cells"), subretinal infiltrates, and retinal pigment epithelial detachment.

Diagnosis of VRL requires:

• Vitreous biopsy (vitrectomy): Obtained by diagnostic pars plana vitrectomy; cytology and flow cytometry of the vitreous sample. MYD88 L265P mutation analysis of vitreous fluid has high diagnostic sensitivity and can confirm the diagnosis even when cytology is equivocal.
• IL-10/IL-6 ratio: VRL cells secrete predominantly IL-10, whereas inflammatory conditions secrete IL-6. IL-10 >50 pg/mL or IL-10:IL-6 ratio >1 strongly suggests VRL.

Treatment of VRL includes intravitreal methotrexate and/or rituximab injections, combined with systemic HD-MTX-based chemotherapy to address concurrent or potential CNS disease. Ocular radiation is used in refractory VRL. All patients with VRL require MRI brain with contrast and CSF evaluation at diagnosis.

Back to Table of Contents

7. Diagnosis and Workup

The diagnostic workup for suspected PCNSL is systematic and aims to confirm tissue diagnosis, stage disease within the CNS, exclude systemic lymphoma, and assess organ function prior to treatment:

• Stereotactic brain biopsy: The cornerstone of diagnosis. A stereotactic needle biopsy provides tissue for histology, immunophenotyping (CD20+, CD79a+, BCL2+, BCL6+, MUM1/IRF4+), and molecular analysis (MYD88 L265P, CD79B). Open resection is NOT performed — it does not improve outcomes and delays chemotherapy.
• Ophthalmologic evaluation (mandatory): Slit-lamp examination and fundoscopy by an ocular oncologist at diagnosis to detect concurrent VRL, even in asymptomatic patients.
• CSF analysis: Lumbar puncture for cytology, flow cytometry, and CSF protein/glucose. Cytology is positive in only 10–30% of cases at diagnosis. Cell-free DNA analysis for MYD88 L265P mutation in CSF is an emerging high-sensitivity tool. CSF should not be obtained before MRI (risk of herniation in the presence of large lesions).
• Bone marrow biopsy: To exclude systemic lymphoma with secondary CNS involvement. Systemic DLBCL with CNS involvement requires different staging and treatment (R-CHOP-based) from true PCNSL.
• Whole-body PET-CT or CT chest/abdomen/pelvis: To rule out systemic lymphoma.
• Testicular ultrasound (males): The testis is an immune-privileged site (similar to the CNS) and a site of occult DLBCL that can involve the CNS; detection alters staging and management.
• Laboratory: HIV serology, LDH (prognostic), CBC, comprehensive metabolic panel, serum protein electrophoresis, creatinine (critical before high-dose methotrexate).

Back to Table of Contents

8. Critical: Steroids Before Biopsy — The "Ghost Tumor" Problem

One of the most important and frequently violated principles in the management of suspected PCNSL is: do not administer corticosteroids before obtaining tissue biopsy unless the patient is deteriorating from raised intracranial pressure and herniation is imminent.

The reason is fundamental to PCNSL biology: lymphoma cells express glucocorticoid receptors and are acutely sensitive to corticosteroids, which induce rapid lymphoma cell apoptosis and mobilization out of the CNS parenchyma. Within 24–72 hours of dexamethasone administration, PCNSL lesions can shrink by >50%, become non-enhancing, or disappear entirely on MRI — the "ghost tumor" phenomenon. When subsequent stereotactic biopsy is performed on this shrunken or invisible lesion, the sample may contain only reactive inflammatory cells, gliosis, and rare residual lymphoma cells — insufficient for diagnosis.

The clinical consequence is devastating: the diagnosis is delayed by weeks to months as the patient undergoes repeat imaging, a second biopsy (after steroid washout), and empiric treatments that may be inappropriate. In a patient with brain mass, cognitive change, and homogeneously enhancing periventricular lesion, the clinical probability of PCNSL is high enough that steroid administration — even for presumed "vasogenic edema" — warrants urgent neurosurgical consultation for same-day or next-day biopsy first.

If steroids have already been given: wait for steroid washout (minimum 2–4 weeks if feasible), repeat MRI, and rebiopsy when enhancing tissue is again visible. Some centers use dexamethasone-free protocols perioperatively, substituting mannitol for acute ICP management.

Back to Table of Contents

9. Treatment

The treatment of PCNSL requires chemotherapy agents capable of adequate CNS penetration. The cornerstone of induction therapy is high-dose methotrexate (HD-MTX), which crosses the blood-brain barrier when administered in doses of 3–8 g/m² (approximately 100–1000 times higher than doses used for rheumatoid arthritis or maintenance in ALL). At these doses, CSF MTX levels approach therapeutic concentrations for lymphoma cell killing:

• HD-MTX-based induction regimens: The MATRix regimen (methotrexate + cytarabine + thiotepa + rituximab) has become a widely used standard after the IELSG32 phase II trial demonstrated superior complete response rates (49%) compared to MTX + cytarabine alone. Rituximab (anti-CD20) is incorporated despite uncertain CNS penetration because CD20 is universally expressed on PCNSL and some rituximab may reach the CNS.
• Role of rituximab: PCNSL cells express CD20; rituximab is included in most modern regimens despite the blood-brain barrier. Intrathecal rituximab (administered via lumbar puncture or Ommaya reservoir) has shown activity in leptomeningeal disease.
• Whole brain radiation therapy (WBRT): Historically the cornerstone of consolidation therapy after induction chemotherapy. However, WBRT is associated with severe delayed neurotoxicity — particularly in patients over 60 years — including progressive cognitive decline, dementia, ataxia, and urinary incontinence. This has led to a significant shift away from WBRT consolidation toward chemotherapy-only consolidation in eligible patients.
• High-dose chemotherapy + autologous stem cell transplant (HD-ASCT): In younger fit patients (<65–70 years) who achieve complete remission with induction, HD-ASCT (using BEAM or thiotepa-based conditioning) provides durable remission with acceptable neurotoxicity. The MSKCC and IELSG32-II data support thiotepa-based conditioning regimens for PCNSL. This approach has increasingly replaced WBRT as consolidation in fit patients.
• Reduced-dose WBRT: For patients not eligible for HD-ASCT, reduced-dose WBRT (23.4 Gy) may be used as consolidation in complete responders, with lower neurotoxicity than conventional 45 Gy. Consolidation chemotherapy alone (cytarabine-based) is an alternative.
• BTK inhibitors (ibrutinib): Highly active in relapsed/refractory PCNSL due to the prevalence of MYD88 and CD79B mutations activating BCR/NF-κB signaling. CNS penetration is confirmed. Response rates of 50–75% in early trials. Combination ibrutinib + HD-MTX regimens are under investigation in frontline settings (the LYSA BLOCAGE-01 trial).
• Intrathecal chemotherapy: Intrathecal methotrexate or cytarabine (via lumbar puncture or Ommaya reservoir) is used for leptomeningeal disease. Its role in the absence of leptomeningeal involvement is controversial when HD-MTX systemic therapy is used.
• HIV-associated PCNSL: Treatment is fundamentally different. Initiating or optimizing cART is the first priority — restoring immune function can itself cause lymphoma regression. Concurrent HD-MTX-based chemotherapy is used in patients with adequate functional status; outcome remains poor with median survival 6–12 months, though cART initiation has substantially improved outcomes compared to the pre-cART era.

Back to Table of Contents

10. Prognosis

The prognosis of PCNSL has improved substantially over the past two decades with modern HD-MTX-based therapy and HD-ASCT consolidation, but remains poor compared to systemic DLBCL. Overall 5-year survival for immunocompetent PCNSL in modern series is approximately 30–40%. Prognostic factors are captured in validated scoring systems:

• IELSG prognostic score: Five adverse factors (age >60, ECOG performance status >1, elevated LDH, elevated CSF protein, involvement of deep brain structures). Patients with 0–1 factors have 2-year OS ~80%; those with 4–5 factors have 2-year OS ~15%.
• Memorial Sloan Kettering score: Incorporates age and Karnofsky performance score; useful for treatment allocation decisions.
• Favorable factors: Younger age (<60), good performance status, low LDH, complete response to induction, MYD88 L265P mutation (associated with better response to HD-MTX in some series).
• Relapse: PCNSL has a high relapse rate; approximately 35–50% of patients relapse within 5 years. Salvage options include ibrutinib (for BCR pathway mutation-positive disease), re-induction with HD-MTX (for late relapse), HD-ASCT (if not previously performed), PD-1 inhibitors (pembrolizumab — early data), and palliative WBRT. Median OS after relapse is 3–6 months in most series, highlighting the importance of durable first-line therapy.
• Neurotoxicity: A major survivorship concern; patients who received WBRT or prolonged methotrexate therapy are at risk for leukoencephalopathy, cognitive decline, gait disturbance, and urinary incontinence. Neuropsychological monitoring is recommended during follow-up.

Back to Table of Contents

Key Research Papers

1. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21(2):266–272. PMID: 12525518 | DOI: 10.1200/JCO.2003.09.036
2. Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the IELSG32 phase 2 trial. Lancet Haematol. 2016;3(5):e217–e227. PMID: 27132696 | DOI: 10.1016/S2352-3026(16)00036-3
3. Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403–1410. PMID: 25568347 | DOI: 10.1182/blood-2014-10-604561
4. Nayak L, Batchelor TT. Recent advances in treatment of primary central nervous system lymphoma. Curr Treat Options Oncol. 2013;14(4):539–552. PMID: 23828011 | DOI: 10.1007/s11864-013-0246-2
5. Grommes C, Pastore A, Palaskas N, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7(9):1018–1029. PMID: 28619981 | DOI: 10.1158/2159-8290.CD-17-0613
6. Nakamura M, Kishi M, Sakaki T, et al. Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res. 2003;63(4):737–741. PMID: 12591720
7. Montesinos-Rongen M, Küppers R, Schlüter D, et al. Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol. 1999;155(6):2077–2086. PMID: 10595939 | DOI: 10.1016/S0002-9440(10)65527-1
8. DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002;20(24):4643–4648. PMID: 12488408 | DOI: 10.1200/JCO.2002.06.013
9. Jahnke K, Thiel E, Martus P, et al. Relapsed primary central nervous system lymphoma: a multicenter study of treatment outcomes. Ann Neurol. 2006;59(5):773–780. PMID: 16634056 | DOI: 10.1002/ana.20828
10. Citterio G, Reni M, Gatta G, Ferreri AJ. Primary central nervous system lymphoma. Crit Rev Oncol Hematol. 2015;93(2):51–67. PMID: 25244795 | DOI: 10.1016/j.critrevonc.2014.09.001
11. Grimm SA, Pulido JS, Jahnke K, et al. Primary intraocular lymphoma: an International Primary CNS Lymphoma Collaborative Group Report. Ann Oncol. 2007;18(11):1851–1855. PMID: 17766693 | DOI: 10.1093/annonc/mdm340
12. Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 2010;75(17):1560–1566. PMID: 20975057 | DOI: 10.1212/WNL.0b013e3181f96282

Back to Table of Contents

PubMed Topic Searches

1. Primary CNS lymphoma treatment
2. PCNSL high-dose methotrexate
3. PCNSL MYD88 mutation
4. PCNSL HIV AIDS
5. Vitreoretinal lymphoma diagnosis
6. CNS lymphoma ibrutinib BTK
7. PCNSL autologous stem cell transplant
8. PCNSL whole brain radiation neurotoxicity
9. PCNSL DLBCL immunocompetent
10. Post-transplant CNS lymphoproliferative
11. PCNSL stereotactic biopsy
12. EBV CNS lymphoma immunocompromised

Back to Table of Contents

Connections

• Cancer Overview
• Glioblastoma
• Multiple Sclerosis
• HIV/AIDS
• Epstein-Barr Virus
• Metastatic Cancers
• Brain Tumors
• Non-Hodgkin Lymphoma
• Hodgkin Lymphoma
• Meningitis
• Toxoplasmosis
• Neuroendocrine Tumors

Back to Table of Contents

Featured Videos